<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719758</url>
  </required_header>
  <id_info>
    <org_study_id>533-CL-005</org_study_id>
    <nct_id>NCT00719758</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study of TRK-100STP</brief_title>
  <official_title>TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of AST-120 on the PK of TRK-100STP, and
      to evaluate the safety and tolerability of TRK-100STP alone or in combination with AST-120
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-blinded, randomized and crossover study to evaluate pharmacokinetic interaction between
      TRK-100STP and AST-120 in different administration condition. Nonelderly adult volunteers
      will receive TRK-100STP with or without AS-T120 after meal. Safety parameters will
      concurrently be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters (vital signs, ECG, laboratory tests)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRK-100STP (BERASUS LA)</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>beraprost</other_name>
    <other_name>Careload LA</other_name>
    <other_name>BERASUS LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-120 (Kremezin®)</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Kremezin®</other_name>
    <other_name>sopherical carbon adsorbent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Body Mass Index (BMI) of ≥17.6 to ≤26.4 kg/m2 and weight of ≥50 to ≤80 kg

        Exclusion Criteria:

          -  Clinical abnormal physical findings, including BP, pulse rate, ECG and laboratory
             assessments

          -  Receives any investigational medicine within 120 days before screening

          -  Recent blood donor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma Inc.</organization>
  </responsible_party>
  <keyword>TRK-100STP,</keyword>
  <keyword>beraprost sodium,</keyword>
  <keyword>Careload LA</keyword>
  <keyword>AST-120</keyword>
  <keyword>Spherical carbon adsorbent</keyword>
  <keyword>Drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

